Archived Press Releases – 2016

4D Molecular Therapeutics Enrolls First Patient in Natural History Study in Lead Clinical Program to Develop Gene Therapy Treatment for Choroideremia

Intravitreal delivery to the retina is critical to Choroideremia treatment Emeryville, CA | December 23, 2016 — 4D Molecular Therapeutics (4DMT), a leader in gene therapy product discovery and development, today announced the enrollment of the first participant in its ...

4D Molecular Therapeutics and the Choroideremia Research Foundation Partner to Develop Gene Therapy Treatment for Choroideremia

Intravitreal delivery to the retina is critical to Choroideremia treatment Emeryville, CA | February 23, 2016 — 4D Molecular Therapeutics (4DMT), a leader in Adeno-Associated Virus (AAV) gene therapy vector discovery and product development, and the Choroideremia Research Foundation (CRF), a ...

4D Molecular Therapeutics Announces Collaboration with Pfizer Inc. for Cardiac Gene Therapy Vector Discovery and Development

Leader in proprietary gene therapy vector discovery closes fifth partnership Emeryville, CA, Jan 7, 2016 — 4D Molecular Therapeutics (4DMT), a leader in Adeno-Associated Virus (AAV) gene therapy vector discovery and product development, today announced both an investment by and ...